<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203876</url>
  </required_header>
  <id_info>
    <org_study_id>CA223-030</org_study_id>
    <nct_id>NCT03203876</nct_id>
  </id_info>
  <brief_title>A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lirilumab in combination with nivolumab or
      in combination with nivolumab and ipilimumab is safe in the treatment of advanced and/or
      metastatic solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">September 4, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of laboratory test toxicity grade shifting from baseline</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of laboratory test toxicity grade shifting from baseline</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum observed concentration (Cmax)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the Pharmacokinetic (PK) of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK and immunogenicity of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of an exposure measure at steady-state to that after the first dose (AI)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T-HALF)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the preliminary anti-tumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the preliminary anti-tumor activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of lirilumab in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum observed concentration (Cmax)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of an exposure measure at steady-state to that after the first dose (AI)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T-HALF)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To characterize the PK of lirilumab given in combination with nivolumab and ipilimumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Part One Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lirilumab and Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lirilumab, Nivolumab and Ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lirilumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part One Combination Therapy</arm_group_label>
    <arm_group_label>Part 2 Combination Therapy</arm_group_label>
    <other_name>BMS-986015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part One Combination Therapy</arm_group_label>
    <arm_group_label>Part 2 Combination Therapy</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2 Combination Therapy</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

          -  Participants must have histologic or cytologic confirmation of a solid malignancy that
             is advanced (metastatic and/or unresectable)

          -  Presence of at least 1 lesion with measurable disease as defined by response
             evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria for response
             assessment

          -  The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Participants with untreated central nervous system (CNS) metastases

          -  Participants with an active, known, or suspected autoimmune disease

          -  Uncontrolled or significant cardiovascular disease

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>6500017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

